ChipokiaTech news, without the noise
← All stories
Ars Technica·

Moderna and Merck say their mRNA cancer vaccine cut death, recurrence by 42%

Markers released top-line results today after previously reporting the trial succeeded.

Preview courtesy of Ars Technica. The full article opens on their site.

Other coverage of this story

More from Ars Technica